|
業務類別
|
Biotechnology |
|
業務概覽
|
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance itssignature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration. |
| 公司地址
| 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 871-4880 |
| 傳真號碼
| -- |
| 公司網頁
| https://metagenomi.co |
| 員工數量
| 119 |
| Mr. Matthew L. Wein, J.D. |
General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary |
美元 407.15K |
27/04/2026 |
| Dr. Jian Irish, M.B.A.,PhD |
President, Chief Executive Officer and Director |
美元 570.66K |
27/04/2026 |
| Ms. Pamela Wapnick, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 464.00K |
27/04/2026 |
|
|
| Dr. Willard H. Dere, M.D. |
Chairman of the Board |
27/04/2026 |
| Dr. Juergen Eckhardt, M.B.A.,M.D. |
Independent Director |
27/04/2026 |
| Dr. Jian Irish, M.B.A.,PhD |
President, Chief Executive Officer and Director |
27/04/2026 |
| Mr. Eric H. Bjerkholt, M.B.A. |
Independent Director |
27/04/2026 |
| Dr. Laurence E. Reid, PhD |
Independent Director |
27/04/2026 |
| Dr. Brian C. Thomas, PhD |
Director |
27/04/2026 |
|
|
|
|
